Isofol Medical AB
Arvid Wallgrens Backe 20
22 articles with Isofol Medical AB
Isofol Announces Presentation on the Global Phase 3 Study of Arfolitixorin in Metastatic Colorectal Cancer at 2019 ESMO Congress
Isofol Medical AB, announced a poster presentation on the ongoing global Phase 3 AGENT clinical study in patients with metastatic colorectal cancer.
Isofol Medical AB announced that an abstract highlighting the study design of its ongoing pivotal/registration-based AGENT clinical study in metastatic colorectal cancer will be presented at the European Society for Medical Oncology 2019 Congress, to be held from September 27 to October 1, 2019, in Barcelona, Spain.
Isofol Announces Management Team Evolution With Appointment of Dr. Roger Tell as Chief Medical Officer
Isofol Medical AB announced the appointment of Roger Tell, M.D., Ph.D. as Chief Medical Officer (CMO), in addition to his responsibilities as Chief Scientific Officer (CSO).
Isofol Medical AB, announced the outcome of an advisory board meeting held to discuss the current status and ongoing strategy for the development of arfolitixorin, the company's proprietary drug candidate being studied in the global pivotal Phase 3 AGENT study for advanced colorectal cancer.
Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a Clinical Use Patent for arfolitixorin in the United States.
6/14/2019Biotech and pharma companies strengthen their leadership teams and boards with new hires and appointments.
Isofol Medical AB, announced the election of three new members to its Board of Directors: Anna Belfrage, MBA, Pär-Ola Mannefred, MBA, and Robert Marchesani, MBA.
Isofol Medical AB (publ), (Nasdaq First North Premier: ISOFOL), today announced approval of a clinical patent for arfolitixorin in the United States.
Isofol Medical AB,, today announced that all senior executives and employees participated in Isofol's share warrant program "2018".
Isofol Reports Early Tumor Shrinkage in Patients With Colorectal Cancer in Phase 1/2a Open Label Extension Study with Arfolitixorin
Isofol Medical AB (publ), announced positive results from an open-label extension study for the ISO-CC-005 Phase 1/2a study of arfolitixorin in patients with metastatic colorectal cancer (mCRC)
First Patient Enrolled in Isofol's Pivotal Phase 3 AGENT Study in 1st Line Metastatic Colorectal Cancer
AGENT is a randomized, controlled, multi-centre study with blinded independent review of the tumour response.
11/26/2018In a short week leading up to Thanksgiving, several companies made leadership changes as they eye the coming year. We round up who made power moves this past week.
11/19/2018Companies bolstered their leadership with additions to boards of directors and c-suite offices.
Isofol Medical AB Release: FDA Clears Company’s IND Application To Start Clinical Program Within Colorectal Cancer With Modufolin
Isofol Medical AB Has Successfully Advanced To The Next Dose Level Of Modufolin In A Phase I/II Clinical Trial In Colorectal Cancer
Isofol Medical AB Announces Successful Meetings With European And US Regulatory Authorities Regarding The Design Of A Pivotal Phase II Clinical Trial Of Isofol's Lead Drug Candidate, Modufolin
Isofol Medical AB Share Issue Oversubscribed, Securing Over SEK 39 Million To Strengthen The Ongoing Phase II Clinical Development Program Of Modufolin
Patent Covering The Use And Pharmaceutical Composition Of Isofol Medical AB’s Lead Drug Candidate, Modufolin, Allowed By United States Patent And Trademark Office
Isofol Medical AB Release: First Patient Successfully Treated With Modufolin As A Rescue Therapy With High Dose Methotrexate (HDMTX) Treatment In Osteosarcoma
Isofol Medical AB Appoints The Sage Group To Identify Strategic Partnerships For Its Novel Modufolin® Chemotherapy Asset